Versatile pharmacological actions of YC-1: anti-platelet to anticancer
Versatile pharmacological actions of YC-1: anti-platelet to anticancer
复制标题
DOI：
10.1016/j.canlet.2004.01.005
复制
发表时间：
2004-04-15
期刊：
影响因子：
9.7
通讯作者：
Park, JW
中科院分区：
文献类型：
--
作者：
Chun, YS;Yeo, EJ;Park, JW
自1994年发表关于YC-1的第一篇文章以来，它已被广泛用作激活可溶性鸟苷酸环化酶和增加培养细胞或分离组织中的环GMP水平的药理学工具。就YC-1的药理作用而言，以往的研究往往限于其抑制血小板聚集和血管收缩。然而，最近的研究表明，YC-1除了抗血小板和血管舒张作用外，还具有多种药理作用。特别是，最近的两份报告表明，YC-1可以被开发为一类新的抗癌剂，用于快速生长的实体瘤，因为它抑制缺氧诱导因子1（HIF-1）的活性，并已报告在体内停止肿瘤生长。我们在这里综述了YC-1的循环GMP依赖性和独立药理作用及其抗HIF-1、抗癌作用。(C)2004爱思唯尔爱尔兰有限公司保留所有权利。
Since the first article on YC-1 was published in 1994, it has been popularly used as a pharmacological tool to activate soluble guanylate cyclase and to increase cyclic GMP levels in cultured cells or isolated tissues. In terms of the pharmacological actions of YC-1, previous studies tend to be limited to its inhibition of platelet aggregation and vascular contraction. However, recent studies have demonstrated that YC-1 has versatile pharmacological effects other than the anti-platelet and vasodilatory effects. In particular, two recent reports suggest that YC-1 could be developed as a new class of anticancer agent for rapidly growing solid tumors, because it inhibits hypoxia-inducible factor 1 (HIF-1) activity, and has been reported to halt tumor growth in vivo. We here review the cyclic GMP-dependent and independent pharmacological actions of YC-1, and its anti-HIF-1, anticancer effect. (C) 2004 Elsevier Ireland Ltd. All rights reserved.